Oryzon Genomics - Planning iadademstat’s path to market
Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific...
1k Views
Oryzon Genomics - Large response benefit consistent in ALICE trial
On 11 June 2021, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual Congress of...
909 Views
Oryzon Genomics - Final update from Phase IIa CLEPSIDRA trial
On 17 September Oryzon presented an update from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, in combination with...
169 Views
Oryzon Genomics - Third positive update from Phase II ALICE trial
Last Friday, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual 25th Congress...
110 Views
Oryzon Genomics - More data support vafidemstat for aggression
On 3 April 2020, Oryzon reported interim data for the first time from its two Phase IIa trials REIMAGINE-AD and ETHERAL. Both explore the company’s...
303 Views